Cancer & SURVIVEiT News

The SURVIVEiT® NewsRoom provides patients with quick access to exclusive news, treatment breakthroughs, survivor stories, and expert interviews providing the latest insight about this rapidly evolving industry. Visit our NewsRoom often and follow us on Facebook.

Blog_how-a-leukemia-diagnosis

How A Leukemia Diagnosis Led To Donor Awareness & A Clothing Line

There were over 414,000 people living with leukemia in the United States in 2016, according to the National Cancer Institute. This particular type of cancer is found in blood and...
547016675

Risk of Developing Ovarian Cancer, Symptoms & New Guidelines For Testing

Given the new screening recommendations, and the fact that it's Ovarian Cancer Awareness Month, we wanted to provide the latest information on BRCA testing, implications, symptoms, risk of developing ovarian...
Caregiver_01

Tips For Coping With A Cancer Diagnosis

Coping with a cancer diagnosis seems like a huge undertaking. Not to mention, nobody asked you if you wanted to take it on. Cancer seems to find us when we...

A Skin Cancer Survivor Shares 3 Ways To Protect Your Skin

One of the many powerful cancer resources we have access to is each other. Cancer patients, cancer survivors and cancer caregivers all have information based on their personal experience. When...
FDA_Drug_Newsroom

FDA approves Bayer’s Nubeqa® (darolutamide), for non-metastatic castration-resistant prostate cancer

FDA approves Bayer's Nubeqa® (darolutamide), a new treatment for men with non-metastatic castration-resistant prostate cancer WHIPPANY, N.J., July 30, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today approved Nubeqa® (darolutamide), an...
FDA_Drug_Newsroom

FDA Approves Pembrolizumab for PD-L1+ Esophageal Squamous Cell Carcinoma

FDA Approves Pembrolizumab for PD-L1+ Esophageal Squamous Cell Carcinoma The FDA has approved pembrolizumab (Keytruda) monotherapy as a treatment for patients with recurrent, locally advanced, or metastatic esophageal squamous cell...
SURVIVEiT_Blog_1_Header

SURVIVEiT® – What Role Will You Play?

At SURVIVEiT, we believe that everyone deserves access to the very best in cancer care and we believe that everyone can be their best advocate, with a little help from...
SURVIVEiT_Blog_2_Header

SURVIVEiT® – How Can You Encourage Others to Support?

In our first blog post, we spoke about how you as an individual can help support SURVIVEiT and our vision that everyone deserves access to the very best in cancer...

SURVIVEiT® – Giving Week 2019

At SURVIVEiT, we believe that everyone deserves access to the very best in cancer care and we believe that everyone can be their best advocate, with a little help from...
insightful_breath

“What Was That Again?”

SURVIVEiT Advisory Chair, Peggy Pollock updated her blog with a new update on her latest lung cancer biopsy report and processing updates: What Was That Again? -Peggy Pollock Dennis, The Insightful...
FDA_Drug_Newsroom

FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma

FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma On June 10, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck) for the first-line treatment...
FDA_Drug_Newsroom

FDA approves pembrolizumab for metastatic small cell lung cancer

FDA approves pembrolizumab for metastatic small cell lung cancer On June 17, 2019, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck) for patients with metastatic small...